These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 15141019)
1. Different DNA lesions trigger distinct cell death responses in HCT116 colon carcinoma cells. Bai S; Goodrich DW Mol Cancer Ther; 2004 May; 3(5):613-9. PubMed ID: 15141019 [TBL] [Abstract][Full Text] [Related]
2. The DNA minor groove-alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells. Cao PR; McHugh MM; Melendy T; Beerman T Mol Cancer Ther; 2003 Jul; 2(7):651-9. PubMed ID: 12883038 [TBL] [Abstract][Full Text] [Related]
3. Induction of DNA damage responses by adozelesin is S phase-specific and dependent on active replication forks. Liu JS; Kuo SR; Beerman TA; Melendy T Mol Cancer Ther; 2003 Jan; 2(1):41-7. PubMed ID: 12533671 [TBL] [Abstract][Full Text] [Related]
4. Induction by adozelesin and hydroxyurea of origin recognition complex-dependent DNA damage and DNA replication checkpoints in Saccharomyces cerevisiae. Weinberger M; Trabold PA; Lu M; Sharma K; Huberman JA; Burhans WC J Biol Chem; 1999 Dec; 274(50):35975-84. PubMed ID: 10585487 [TBL] [Abstract][Full Text] [Related]
5. Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity. Woynarowski JM; Napier C; Trevino AV; Arnett B Biochemistry; 2000 Aug; 39(32):9917-27. PubMed ID: 10933811 [TBL] [Abstract][Full Text] [Related]
6. Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay. Hidalgo M; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD Anticancer Drugs; 1999 Mar; 10(3):295-302. PubMed ID: 10327036 [TBL] [Abstract][Full Text] [Related]
7. Adozelesin triggers DNA damage response pathways and arrests SV40 DNA replication through replication protein A inactivation. Liu JS; Kuo SR; McHugh MM; Beerman TA; Melendy T J Biol Chem; 2000 Jan; 275(2):1391-7. PubMed ID: 10625690 [TBL] [Abstract][Full Text] [Related]
8. Activation of budding yeast replication origins and suppression of lethal DNA damage effects on origin function by ectopic expression of the co-chaperone protein Mge1. Trabold PA; Weinberger M; Feng L; Burhans WC J Biol Chem; 2005 Apr; 280(13):12413-21. PubMed ID: 15647270 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis. Pan Y; Ren KH; He HW; Shao RG Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782 [TBL] [Abstract][Full Text] [Related]
10. DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, hedamycin, a pluramycin antitumor antibiotic. Tu LC; Melendy T; Beerman TA Mol Cancer Ther; 2004 May; 3(5):577-85. PubMed ID: 15141015 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin. Cobuzzi RJ; Burhans WC; Beerman TA J Biol Chem; 1996 Aug; 271(33):19852-9. PubMed ID: 8702695 [TBL] [Abstract][Full Text] [Related]
12. Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Lee CS; Pfeifer GP; Gibson NW Biochemistry; 1994 May; 33(19):6024-30. PubMed ID: 8180230 [TBL] [Abstract][Full Text] [Related]
13. DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Lee CS; Gibson NW Cancer Res; 1991 Dec; 51(24):6586-91. PubMed ID: 1742731 [TBL] [Abstract][Full Text] [Related]
14. Comparison of checkpoint responses triggered by DNA polymerase inhibition versus DNA damaging agents. Liu JS; Kuo SR; Melendy T Mutat Res; 2003 Nov; 532(1-2):215-26. PubMed ID: 14643438 [TBL] [Abstract][Full Text] [Related]
15. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects. Bhuyan BK; Smith KS; Adams EG; Wallace TL; Von Hoff DD; Li LH Cancer Chemother Pharmacol; 1992; 30(5):348-54. PubMed ID: 1505072 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks. Foster BJ; LoRusso PM; Poplin E; Zalupski M; Valdivieso M; Wozniak A; Flaherty L; Kasunic DA; Earhart RH; Baker LH Invest New Drugs; 1996; 13(4):321-6. PubMed ID: 8824350 [TBL] [Abstract][Full Text] [Related]
17. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359 [TBL] [Abstract][Full Text] [Related]
18. Antitumor drug adozelesin differentially affects active and silent origins of DNA replication in yeast checkpoint kinase mutants. Wang Y; Beerman TA; Kowalski D Cancer Res; 2001 May; 61(9):3787-94. PubMed ID: 11325853 [TBL] [Abstract][Full Text] [Related]
19. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907 [TBL] [Abstract][Full Text] [Related]
20. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells. Bhuyan BK; Smith KS; Adams EG; Petzold GL; McGovren JP Cancer Res; 1992 Oct; 52(20):5687-92. PubMed ID: 1394193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]